-
Mario
Ammirati,
J.
Galicich,
Ehud
Arbit,
Youlian
Liao
(1987)
Reoperation in the treatment of recurrent intracranial malignant gliomas.
Neurosurgery, 21 5
-
R.
Zuniga,
R.
Torcuator,
R.
Jain,
Joseph
Anderson,
Thomas
Doyle,
S.
Ellika,
L.
Schultz,
T.
Mikkelsen
(2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
Journal of Neuro-Oncology, 91
-
A.
Jemal,
R.
Siegel,
Elizabeth
Ward,
Y.
Hao,
Jiaquan
Xu,
Taylor
Murray,
M.
Thun
(2008)
Cancer Statistics, 2008
CA: A Cancer Journal for Clinicians, 58
-
J.
Buckner
(2003)
Factors influencing survival in high-grade gliomas.
Seminars in oncology, 30 6 Suppl 19
-
(2008)
Irinotecaninduced central nervous system toxicity
-
C.
Balmaceda,
D.
Peereboom,
S.
Pannullo,
Y.
Cheung,
P.
Fisher,
J.
Alavi,
M.
Sisti,
Johnson
Chen,
R.
Fine
(2008)
Multi‐institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high‐grade gliomas
Cancer, 112
-
R.
Stupp,
Warren
Mason,
M.
Bent,
M.
Weller,
B.
Fisher,
M.
Taphoorn,
K.
Bélanger,
A.
Brandes,
C.
Marosi,
U.
Bogdahn,
J.
Curschmann,
Robert
Janzer,
Samuel
Ludwin,
T.
Gorlia,
A.
Allgeier,
D.
Lacombe,
J.
Cairncross,
E.
Eisenhauer,
R.
Mirimanoff
(2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
The New England journal of medicine, 352 10
-
Arnoud
Kappelle,
T.
Postma,
M.
Taphoorn,
G.
Groeneveld,
M.
Bent,
C.
Groeningen,
B.
Zonnenberg,
K.
Sneeuw,
J.
Heimans
(2001)
PCV chemotherapy for recurrent glioblastoma multiforme
Neurology, 56
-
P.
Hamberg,
F.
Jong,
D.
Brandsma,
J.
Verweij,
S.
Sleijfer
(2008)
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature
Acta Oncologica, 47
-
Barker
Fg,
Chang
Sm,
Gutin
Ph,
Malec
Mk,
Mcdermott
Mw,
Prados
Md,
Wilson
Cb
(1998)
Survival and functional status after resection of recurrent glioblastoma multiforme.
Neurosurgery, 42 4
-
Eric
Wong,
K.
Hess,
M.
Gleason,
K.
Jaeckle,
A.
Kyritsis,
M.
Prados,
V.
Levin,
W.
Yung
(1999)
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 8
-
M.
Chamberlain
(2004)
Salvage Chemotherapy with CPT-11 for Recurrent Glioblastoma Multiforme
Journal of Neuro-Oncology, 56
-
H.
Friedman,
M.
Prados,
P.
Wen,
T.
Mikkelsen,
D.
Schiff,
L.
Abrey,
W.
Yung,
N.
Paleologos,
M.
Nicholas,
R.
Jensen,
J.
Vredenburgh,
Jane
Huang,
M.
Zheng,
T.
Cloughesy
(2009)
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
-
G.
Barbagallo,
M.
Jenkinson,
A.
Brodbelt
(2008)
‘Recurrent’ glioblastoma multiforme, when should we reoperate?
British Journal of Neurosurgery, 22
-
N.
Dubrawsky
(1989)
Cancer statistics
CA: A Cancer Journal for Clinicians, 39
-
Salvage therapy in patients with glioblastoma: is there any benefit?
-
P.
Hau,
U.
Baumgart,
Katharina
Pfeifer,
Annekatrin
Bock,
T.
Jauch,
J.
Dietrich,
K.
Fabel,
O.
Grauer,
C.
Wismeth,
M.
Klinkhammer-Schalke,
M.
Allgäuer,
G.
Schuierer,
H.
Koch,
J.
Schlaier,
Winfried
Ulrich,
A.
Brawanski,
U.
Bogdahn,
A.
Steinbrecher
(2003)
Salvage therapy in patients with glioblastoma
Cancer, 98
-
(2008)
Irinotecaninduced central nervous system toxicity. Report on two cases and review of the literature
-
G.
Harsh,
V.
Levin,
P.
Gutin,
M.
Seager,
P.
Silver,
C.
Wilson
(1987)
Reoperation for recurrent glioblastoma and anaplastic astrocytoma.
Neurosurgery, 21 5
-
M.
Hegi,
A.
Diserens,
T.
Gorlia,
M.
Hamou,
N.
Tribolet,
N.
Tribolet,
M.
Weller,
J.
Kros,
J.
Hainfellner,
W.
Mason,
L.
Mariani,
Jacoline
Bromberg,
P.
Hau,
R.
Mirimanoff,
J.
Cairncross,
R.
Janzer,
R.
Stupp
(2005)
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
The New England Journal of Medicine, 352
-
(2008)
Cancer statistics CA Cancer J Clin
-
T.
Cloughesy,
Emese
Filka,
J.
Kuhn,
G.
Nelson,
F.
Kabbinavar,
H.
Friedman,
L.
Miller,
G.
Elfring
(2003)
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen
Cancer, 97
-
M.
Prados,
K.
Lamborn,
W.
Yung,
K.
Jaeckle,
H.
Robins,
M.
Mehta,
H.
Fine,
P.
Wen,
T.
Cloughesy,
Susan
Chang,
M.
Nicholas,
D.
Schiff,
H.
Greenberg,
L.
Junck,
K.
Fink,
K.
Hess,
J.
Kuhn
(2006)
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Neuro-oncology, 8 2
-
L.
Davidoff
(2005)
Brain tumors
Psychiatric Quarterly, 4
-
H.
Friedman,
W.
Petros,
A.
Friedman,
L.
Schaaf,
T.
Kerby,
Jennifer
Lawyer,
M.
Parry,
Peter
Houghton,
Shelley
Lovell,
Karima
Rasheed,
T.
Cloughsey,
E.
Stewart,
O.
Colvin,
J.
Provenzale,
R.
McLendon,
D.
Bigner,
I.
Cokgor,
Michael
Haglund,
J.
Rich,
D.
Ashley,
Joseph
Malczyn,
G.
Elfring,
L.
Miller
(1999)
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 5